Information on EC 1.3.1.22 - 3-oxo-5alpha-steroid 4-dehydrogenase (NADP+)

Word Map on EC 1.3.1.22
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)

The enzyme appears in viruses and cellular organisms

EC NUMBER
COMMENTARY hide
1.3.1.22
-
RECOMMENDED NAME
GeneOntology No.
3-oxo-5alpha-steroid 4-dehydrogenase (NADP+)
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
a 3-oxo-5alpha-steroid + NADP+ = a 3-oxo-DELTA4-steroid + NADPH + H+
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
oxidation
-
-
-
-
redox reaction
-
-
-
-
reduction
-
-
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
allopregnanolone biosynthesis
-
-
androgen biosynthesis
-
-
cardenolide biosynthesis
-
-
Steroid hormone biosynthesis
-
-
Brassinosteroid biosynthesis
-
-
Metabolic pathways
-
-
Biosynthesis of secondary metabolites
-
-
SYSTEMATIC NAME
IUBMB Comments
3-oxo-5alpha-steroid:NADP+ DELTA4-oxidoreductase
The enzyme catalyses the conversion of assorted 3-oxo-Delta4 steroids into their corresponding 5alpha form. Substrates for the mammalian enzyme include testosterone, progesterone, and corticosterone. Substrates for the plant enzyme are brassinosteroids such as campest-4-en-3-one and (22alpha)-hydroxy-campest-4-en-3-one. cf. EC 1.3.99.5, 3-oxo-5alpha-steroid 4-dehydrogenase (acceptor).
CAS REGISTRY NUMBER
COMMENTARY hide
37255-34-8
-
72412-84-1
-
9029-09-8
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
growth on fermented pistachos, lemons and corn tortillas
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
Sf 9 cell-line
-
-
Manually annotated by BRENDA team
expressed in Arabidopsis thaliana
Swissprot
Manually annotated by BRENDA team
South African clawed frog
-
-
Manually annotated by BRENDA team
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
17-epitestosterone + NADPH
?
show the reaction diagram
-
-
-
-
?
17alpha,21-dihydroxypregn-4-ene-3,11,20-trione + NADPH
17alpha,21-dihydroxy-5alpha-pregnan-3,11,20-trione + NADP+
show the reaction diagram
-
trivial name cortisone
-
ir
17alpha,21-dihydroxypregn-4-ene-3,20-dione + NADPH
17alpha,21-dihydroxy-5alpha-pregnane-3,20-dione
show the reaction diagram
-
-
-
?
17alpha-hydroxyprogesterone + NADPH
17alpha-hydroxy-5alpha-pregnan-3,20-dione + NADP+
show the reaction diagram
-
-
-
-
ir
17beta-methyl-androsta-4,9-dien-3-one + NADPH
17beta-methyl-5alpha-androst-9-en-3-one + NADP+
show the reaction diagram
-
-
-
?
20-alpha-hydroxypregn-4-ene-3one + NADPH
20-alpha-hydroxy-5alpha-pregnan-3-one + NADP+
show the reaction diagram
20alpha-hydroxy-4-pregnen-3-one + NADPH
20alpha-hydroxy-5-beta-pregnan-3-one + NADP+
show the reaction diagram
-
more reactive than progesterone
-
-
?
21-hydroxypregn-4-ene-3,20-dione + NADPH
21-hydroxy-5alpha-pregnan-3,20-dione + NADP+
show the reaction diagram
-
-
-
?
5alpha-pregnan-3,20-dione + NADP+
progesterone + NADPH + H+
show the reaction diagram
-
-
-
-
r
androstenediol + NADPH
5alpha-androstan-3beta,17beta-diol + NADP+
show the reaction diagram
-
-
-
-
ir
androstenedione + NADPH + H+
5alpha-androstan-3,17-dione + NADP+
show the reaction diagram
campestenone + NADPH
5alpha-campestan-3-one + NADP+
show the reaction diagram
reduction at very low levels
-
-
?
cholest-4-en-3-one + NADPH
5-alpha-cholestan-3-one + NADP+
show the reaction diagram
cortexolone + NADPH
17alpha,21-dihydroxy-5alpha-pregnan-3,20-dione + NADP+
show the reaction diagram
-
-
-
-
ir
corticosterone + NADPH + H+
5alpha-dihydrocorticosterone + NADP+
show the reaction diagram
-
-
-
-
?
deoxycorticosterone + NADPH
21-hydroxy-5alpha-pregnan-3,20-dione
show the reaction diagram
epitestosterone + NADPH
?
show the reaction diagram
-
-
-
-
ir
progesterone + NADPH
3alpha-hydroxy-5alpha-pregnan-20-one + NADP+
show the reaction diagram
-
-
-
-
?
progesterone + NADPH
5alpha-pregnan-3,20-dione + NADP+
show the reaction diagram
progesterone + NADPH
5alpha-pregnan-3-20-dione + NADP+
show the reaction diagram
testosterone + NADPH
17beta-hydroxy-5alpha-androstan-3-one + NADP+
show the reaction diagram
testosterone + NADPH
5alpha-dihydrotestosterone + NADP+
show the reaction diagram
testosterone + NADPH
5alpha-dihydrotestosterone + NADP+ + H+
show the reaction diagram
testosterone + NADPH
androstan-3alpha,17beta-diol + androstan-3beta,17beta-diol + 5alpha-dihydrotestosterone
show the reaction diagram
testosterone + NADPH + H+
5alpha-dihydrotestosterone + NADP+
show the reaction diagram
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
5alpha-pregnan-3,20-dione + NADP+
progesterone + NADPH + H+
show the reaction diagram
-
-
-
-
r
progesterone + NADPH
5alpha-pregnan-3-20-dione + NADP+
show the reaction diagram
testosterone + NADPH
17beta-hydroxy-5alpha-androstan-3-one + NADP+
show the reaction diagram
testosterone + NADPH
5alpha-dihydrotestosterone + NADP+
show the reaction diagram
additional information
?
-
-
role of enzyme in initiation of spermatogenensis
-
-
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
coenzyme Q10
-
-
NADP+
-
-
additional information
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
K+
-
stimulate
Li+
-
stimulate
Mg2+
-
stimulatory at concentration 1 mM
additional information
-
not dependent on divalent cation
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(+)-methysticin
-
-
(+/-)-LY191704
-
i.e. (4aS,10aR)-7-chloro-1-methyl-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-one, non-steroidal, most potent benzoquinoline mimicing 4-azasteroid inhibitors, and specific for isozyme 5alphaR-1, IC50 is 30 nM
(-)-epigallocatechin-3-gallate
-
i.e. EGCG, from Thea sativa, slightly inhibits the liver microsomal enzyme
(10bR)-8-chloro-4,10b-dimethyl-4a,5,6,10b-tetrahydrophenanthridin-2(1H)-one
-
isoform II, 49% inhibition at 0.02 mM
(10bR)-8-chloro-4,5,10b-trimethyl-4a,5,6,10b-tetrahydrophenanthridin-2(1H)-one
-
isoform II, 57% inhibition at 0.029 mM
(10bR)-8-chloro-5,10b-dimethyl-4a,5,6,10b-tetrahydrophenanthridin-2(1H)-one
-
isoform II, 42% inhibition at 0.03 mM
(2E,4E,6E,8E)-((2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoate
-
compound shows moderate anti-tumour activity in vivo
(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl palmitoate
-
activity of 3-O-acylated (e)-epigallocatechins increases with the increasing carbon numbers of the fatty acid moiety, reaching maximum for palmitoate
(3R,4R)-3-(1,3-benzodioxol-5-ylmethyl)-4-(1,3,5-benzotrioxepin-6-ylmethyl)tetrahydrofuran-2-ol
-
-
(3R,4R)-3-(1,3-benzodioxol-5-ylmethyl)-4-(1,3,5-benzotrioxepin-7-ylmethyl)tetrahydrofuran-2-ol
-
i.e. (-)-cubebin
(3R,4R)-3-(1,3-benzodioxol-5-ylmethyl)-4-(2,3-dimethoxybenzyl)tetrahydrofuran-2-ol
-
-
(3R,4R)-3-(1,3-benzodioxol-5-ylmethyl)-4-(3,4-dimethoxybenzyl)tetrahydrofuran-2-ol
-
i.e. (-)-3,4-dimethoxy-3,4-desmethylenedioxycubebin
(4aS)-7-chloro-4a-methyl-2,3,4,4a-tetrahydrophenanthrene-2-carboxylic acid
-
-
(4aS,10bS)-4,10b-dimethyl-8-[(E)-2-naphthylylvinyl]-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 6 nM, isoform II, 50% inhibition at 0.00134 mM
(4aS,10bS)-4,10b-dimethyl-8-[(E)-2-phenylvinyl]-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 6 nM, isoform II, 50% inhibition at 0.0014 mM
(4aS,10bS)-4,8-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 11 nM
(4aS,10bS)-8-(2-furyl)-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 59 nM, isoform II, 50% inhibition above 10 nM
(4aS,10bS)-8-bromo-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 35 nM
(4aS,10bS)-8-chloro-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 60 nM
(4aS,10bS)-8-chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 17 nM
(4aS,10bS)-8-chloro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 8 nM, isoform II, 50% inhibition above 0.01 mM
(4aS,10bS)-8-fluoro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 35 nM
(4aS,10bS)-8-methoxy-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 120 nM
(4R)-4,8-dimethyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 312 nM
(4R)-8-chloro-4-methyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 141 nM
(4S)-4,8-dimethyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 137 nM
(5'S)-17beta-(2-chlorophenyl-4,5-dihydrooxazol-5-yl)androst-5-en-3-one
-
-
(5'S)-17beta-(4-bromophenyl-4,5-dihydrooxazol-5-yl)androst-5-en-3-one
-
-
(5alpha,20-R)-4-Diazo-21-hydroxy-20-methylpregnan-3-one
-
RMI18,341
(6R)-8-chloro-6-methyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 188 nM
(Z)-((2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl) hexadec-9-enoate
-
-
1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 298 nM
1-methyl-5-(4-(2-phenylacetyl)phenyl)pyridin-2(1H)-one
-
61% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
10-azasteroids
-
several
11-ketoprogesterone
-
complete inhibition
17-diisopropylcarbamoyl-2-androsten-3-carboxylate
-
-
17-diisopropylcarbamoyl-3,5-androstadien-3-carboxylate
-
-
17-diisopropylcarbamoyl-3-androsten-3-carboxyate
-
-
17-diisopropylcarbamoyl-androstan-3-carboxylate
-
-
17-tert-butylcarbamoyl-3,5-androstadien-3-carbaldehyde
-
-
17-tert-butylcarbamoyl-3,5-androstadien-3-carboxylate
-
dead-end inhibition versus testosterone
17-tert-butylcarbamoyl-3,5-androstadien-3-ol
-
-
17a-(2-propionoxyethyl)-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
0.01 mM, 100% inhibition; 0.01 mM, 8.5% inhibition
17a-allyl-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
0.01 mM, 0.4% inhibition; 0.01 mM, 99% inhibition
17a-ethyl-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
0.01 mM, 100% inhibition; 0.01 mM, 32.3% inhibition
17a-methyl-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
0.01 mM, 18.9% inhibition; 0.01 mM, 99% inhibition
17alpha-hydroxyprogesterone
-
-
17alpha-methyltestosterone
-
-
17alpha-p-bromophenylcarbamoyloxy-4-pregnen-3 20-dione
17alpha-p-bromophenylcarbamoyloxy-4-pregnen-3,20-dione
17alpha-phenylcarbamoyloxy-4-pregnen-3,20-dione
17beta-(N-tert-butylcarbamoyl)androsta-3,5-diene-3-carboxylic acid
-
-
17beta-Carbamoyl-1,3,5(10)-estratriene-3-carboxylic acids
17beta-estradiol
17beta-hydroxyandrosta-1,4-dien-3-one
-
50% inhibition
17beta[3-(N-4-bromophenyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
-
17beta[3-(N-4-chlorophenyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
-
17beta[3-(N-4-ethoxyphenyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
-
17beta[3-(N-4-ethylphenyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
-
17beta[3-(N-4-methoxyphenyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
-
17beta[3-(N-4-phenyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
-
17beta[3-(N-4-tolyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
slight inhibition
19-norandrost-4-ene-3,17-dione
-
complete inhibition
19-nortestosterone
-
complete inhibition
2,4a,9,10-tetrahydrophenanthrene-2-carboxylic acid
-
-
2-(16-(acetylthio)hexadecanamido)ethyl 6-(2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy)acetamido)hex-4-enoate
-
43% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
2-(2-(16-(acetylthio)hexadecanamido)ethoxy)ethyl 6-(2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy)acetamido)hex-4-enoate
-
33% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
20alpha-hydroxypregn-4-en-3-one
-
competitive
21,21-pentamethylene-4-aza-5alpha-pregn-1-ene-3,20-dione
-
i.e. L685,273, suppresses testicular enzyme activity during puberty by 75-86%
3-Androstene-3-carboxylic acids
3beta-(3'-oxapentanoyloxy)-androst-5-en-17-one
-
good in vitro inhibitory activity, but compound does not bind to the androgen receptors
3beta-acetoxyandrost-5-en-17-one
-
good in vitro inhibitory activity, but compound does not bind to the androgen receptors
3beta-hexanoyloxyandrost-5-en-17-one
-
good in vitro inhibitory activity, but compound does not bind to the androgen receptors
4,16-androstadien-3-one
-
-
4,6,8-trimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 15.8 nM
4,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 20 nM
4-(1-[4-[acetyl(methyl)amino]-3-methylphenyl]-1-ethylpropyl)-2-methylphenyl diethylcarbamate
-
22% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]-3-methylphenyl]-1-ethylpropyl)phenyl diethylcarbamate
-
25% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)-2-methylphenyl diethylcarbamate
-
56% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl 4-methylpiperazine-1-carboxylate
-
17% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl azepane-1-carboxylate
-
70% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl azocane-1-carboxylate
-
20% inhibition at 0.001 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl bis(1-methylethyl)carbamate
-
72% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl bis(1-methylpropyl)carbamate
-
22% inhibition at 0.001 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl dibenzylcarbamate
-
51% inhibition at 0.001 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl dibutylcarbamate
-
32% inhibition at 0.001 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl diethylcarbamate
-
57% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl dimethylcarbamate
-
29% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl dipropylcarbamate
-
77% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl morpholine-4-carboxylate
-
15% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl piperidine-1-carboxylate
-
68% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl pyrrolidine-1-carboxylate
-
57% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-methylethyl)phenyl diethylcarbamate
-
16% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-propylbutyl)phenyl diethylcarbamate
-
27% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]cyclobutyl)phenyl diethylcarbamate
-
16% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]cycloheptyl)phenyl diethylcarbamate
-
25% inhibition at 0.01 mM; 46% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]cyclopentyl)phenyl diethylcarbamate
-
5% inhibition at 0.01 mM
4-(2-[5-[(diphenylmethyl)carbamoyl]-1-benzofuran-2-yl]phenoxy)butanoic acid
-
isoform I, 50% inhibition at 310 nM, isoform II, 50% inhibition above 0.1 mM
4-(2-[6-[(diphenylmethyl)carbamoyl]-1-benzofuran-2-yl]phenoxy)butanoic acid
-
isoform I, 50% inhibition at 62 nM, isoform II, 50% inhibition at 270 nM
4-(3-(4-(N-methylacetamido)phenyl)pentan-3-yl)phenyl dibenzylcarbamate
-
competitive inhibitor
4-(4'-formylphenoxy)benzoic acid
4-(biphenyl-4'-yloxy)phenylacetic acid
4-(biphenyl-4'-yloxy)phenylformic acid
4-(N-(diphenyl)acetyl-4-piperidinyloxy)benzoic acid
4-(N-(diphenyl)carbamoyl-4-piperidinyloxy)benzoic acid
4-(N-(tert-butyloxycarbonyl)-4-piperidinyloxy)benzoic acid
4-(N-adamantanoyl-4-piperidinyloxy)benzoic acid
4-Androsten-3-one-17beta-carboxylic acid
-
competitive
4-Aza-4-methyl-5alpha-pregnane-3,20-dione
4-azasteroids
4-bromo-17alpha-(p-fluorobenzoyloxy)-4-pregnene-3,20-dione
-
competitive
4-carboxy-4'-(N,N-dicyclohexyl)-aminobiphenyl
4-carboxy-4'-(N,N-diisobutyl)-aminobiphenyl
4-carboxy-4'-(N,N-diisopropyl)-aminobiphenyl
4-carboxy-4'-(N,N-diphenyl)-aminobiphenyl
4-carboxy-4'-(N-adamantyl)-aminobiphenyl
4-Ene-3-keto-steroids
-
17beta-estradiol in high concentrations functions as an uncompetitive inhibitor
4-MA
active at 0.01 mM
4-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 185 nM
4-methyl-4-azasteroids
-
4-methyl-5,6-dihydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 1400 nM
4-methyl-azasteroid
4-[1-[4-(acetylamino)-3-methylphenyl]-1-ethylpropyl]-2-methylphenyl diethylcarbamate
-
17% inhibition at 0.01 mM
4-[2-(6-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
-
isoform I, 50% inhibition at 50 nM, isoform II, 50% inhibition at 340 nM
4-[2-(6-[[bis(4-methoxyphenyl)methyl]amino]-1-benzofuran-2-yl)phenoxy]butanoic acid
-
isoform I, 50% inhibition at 42 nM, isoform II, 50% inhibition at 480 nM
4-[2-(6-[[bis(4-methoxyphenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
-
isoform I, 50% inhibition at 130 nM, isoform II, 50% inhibition at 930 nM
4-[3-[(2,2-diphenyl-1,3-benzodioxol-5-yl)oxy]-2-methyl-1H-indol-1-yl]butanoic acid
-
isoform I, 50% inhibition at 10 nM, isoform II, 50% inhibition at 6300 nM
5alpha-androstane-3,17-dione
-
30% inhibition
5beta-cholestan-3-one
-
-
6,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 14.3 nM
6-azasteroids
-
several
6-methylene-17alpha-(2-cyclohexylacetoxy)-pregn-4-ene-3,20-dione
-
-
6-methylene-17alpha-(3-cyclohexylpropionyloxy)-pregn-4-ene-3,20-dione
-
-
6-methylene-17alpha-(3-cyclopentylpropionyloxy)-pregn-4-ene-3,20-dione
-
-
6-methylene-17alpha-(4-cyclohexylbutyryloxy)-pregn-4-ene-3,20-dione
-
-
6alpha-methyl-11-ketoprogesterone
-
25% inhibition
6beta-methyl-11-ketoprogesterone
-
50% inhibition
7-bromo-2,4a,9,10-tetrahydrophenanthrene-2-carboxylic acid
-
-
7-chloro-2,4a,9,10-tetrahydrophenanthrene-2-carboxylic acid
-
-
8-bromo-4-methyl-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
50% inhibition at 60 nM, isoform I
8-chloro-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 49 nM
8-chloro-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
50% inhibition at 460 nM, isoform I
8-chloro-1-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 204 nM
8-chloro-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 459 nM
8-chloro-4,5-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 15.6 nM
8-chloro-4,6-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 8.5 nM
8-chloro-4-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 7.6 nM
8-chloro-4-methyl-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
50% inhibition at 30 nM, isoform I
8-chloro-5-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 346 nM
8-chloro-6-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 14.4 nM
8-fluoro-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
50% inhibition at 600 nM, isoform I
8-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 376 nM
8-methyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 176 nM
acrylate episteride
-
AFA131
active at 0.01 mM
AFA192
active at 0.01 mM
AFA27
active at 0.01 mM
AFA76
active at 0.01 mM, most potent inhibitor among non-steroid compounds tested
alpha-4-azasteroids
-
substitution of finasteride N-group by 6-azasteroids increased the rate of inhibition of type-1 5-alpha-reductases
androst-1-ene-3,17dione
-
55% inhibition
androst-4-en-3,17-dione
-
-
androst-4-ene-3,17-dione
-
complete inhibition
androst-4-enedione
-
-
AS601811
active at 0.01 mM
asclepic acid
-
50% inhibition at 0.50 mM
benzoquilizin-3-ones
-
diverse, mimics of 10-azasteroids, overview, structure-activity relationships
benzoquinolines
-
compounds as mimics of 4-azasteroid inhibitors, diverse, overview, compounds derived from 6-azasteroids, overview
beta-sitosterol
-
-
Biochanin A
-
-
Cd2+
-
1 mM: less than 20% inhibition
cholest-5-en-3-one
-
-
cholestanone
-
-
dehydroepiandrosterone
-
good in vitro inhibitory activity, but compound does not bind to the androgen receptors
deoxycorticosterone acetate
-
competitive
Detergents
-
e.g.: Lubrol WX, Nonidet P-40, octyl D-glucopyranoside, L-alpha-lysophosphatidylcholine, CHAPS, concentration-dependent inhibition
dihydrotestosterone
-
significantly decreases 5alpha-R1 mRNA and 5alpha-R2 mRNA expression in female rats
docosanol
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
dutasteride
EDTA
-
slightly inhibitory
epristeride
-
-
estradiol
-
in female genital skin fibroblasts
estradiol-17beta
ethinylestradiol
finasteride
FK143
-
i.e. 4-[3-(3-[[bis-(4-isobutyl-phenyl)-methyl]amino]-benzoyl)-indol-1-yl]-butyric acid, a non-steroidal bi-substrate inhibitor
flavins
-
and flavin analogs, high concentration
-
genistein
-
-
ginsenoside Rg3
-
a unique ginsenoside in red ginseng
ginsenoside Ro
kaikasaponin III
-
0.1 mM, 66.8% inhibition
lauric acid
-
isoform 1, 50% inhibition at 0.0167 mM, isoform 2, 50% inhibition at 0.0186 mM
lauric acid ethyl ester
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
linoleic acid
LY306089
-
a non steroid, non-competitive inhibitor of type I 5alpha-reductase in DU145 cells
MK386
MK434
-
-
Mn2+
-
1 mM: less than 20% inhibition
myristic acid
-
isoform 2, 50% inhibition at 0.004 mM
N(dicyclohexyl)acetylpiperidine-4-(2-methoxybenzylidene-4-carboxylic acid)
-
isoform 1, pH 6.6, 37C, 55% inhibition at 0.01 mM, isoform 2, pH 5.5, 37C, 43% inhibition at 0.01 mM
N,N-bis(1-methylethyl)-4-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzamide
-
isoform I, 50% inhibition at 510 nM, isoform II, 9% inhibition at 0.01 mM
N,N-dicyclohexyl-4-(4'-carboxyphenoxy)benzamide
N,N-diisobutyl-4-(4'-carboxyphenoxy)benzamide
N,N-diisopropyl-2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy)acetamide
-
8% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
N,N-diisopropyl-2-(4-(1-methyl-6-oxopiperidin-3-yl)phenoxy)acetamide
-
6% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
N,N-diisopropyl-2-(4-(2-methyl-4-oxo-3,4-dihydropyridin-1(2H)-yl)phenoxy)acetamide
-
3% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
N,N-diisopropyl-4-(4'-carboxyphenoxy)benzamide
N,N-diphenyl-4-(4'-carboxyphenoxy)benzamide
N-(1-adamantanoyl)piperdine-4-(2-methoxybenzyliden-4-carboxylic acid)
N-(1-adamantanoyl)piperidine-4-(2-fluorobenzylidene-4-carboxylic acid)
N-(3,3-diphenyl)propanoylpiperidine-4-(benzylidene-4-carboxylic acid)
N-(dicyclohexyl)acetylpiperidine-4-(2-fluorobenzylidene-4-carboxylic acid)
N-(dicyclohexyl)acetylpiperidine-4-(2-methoxybenzylidene-4-carboxylic acid)
-
pH 5.5, 37C, DU145 cells, 5% inhibition at 0.01 mM, BPH tissue, 50% inhibition at 0.00013 mM
N-(dicyclohexyl)acetylpiperidine-4-(benzylidene-3-carboxylic acid)
N-(dicyclohexyl)acetylpiperidine-4-(benzylidene-4-acetic acid)
N-(dicyclohexyl)acetylpiperidine-4-(benzylidene-4-carboxylic acid)
N-(diphenyl)acetylpiperidine-4-(2-fluorobenzylidene-4-carboxylic acid)
N-(diphenyl)acetylpiperidine-4-(2-methoxybenzylidene-4-carboxylic acid)
N-(diphenyl)acetylpiperidine-4-(benzylidene-3-carboxylic acid)
N-(diphenyl)acetylpiperidine-4-(benzylidene-4-acetic acid)
N-adamantyl-4-(4'-carboxyphenoxy)benzamide
N-allyl-2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy)acetamide
-
6% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
N-allyl-2-(4-(2-methyl-4-oxo-3,4-dihydropyridin-1(2H)-yl)phenoxy)acetamide
-
8% inhibition of type 1 steroid 5alpha reductase at 0.01 mM and 12% inhibition of type 2 steroid 5alpha reductase at 0.01 mM
N-cyclohexyl-4-(4'-carboxyphenoxy)benzamide
N-phenyl-4-(4'-carboxyphenoxy)benzamide
N-tert-butyl-4-(4'-carboxyphenoxy)benzamide
NADP+
non-steroidal bi-substrate inhibitors
-
several, structures, overview
-
oleic acid
oleic acid ethyl ester
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
ONO 3805
-
-
ONO-3805
-
a non-steroidal bi-substrate inhibitor
p-chloromercuribenzoate
palmitic acid
PD17
active at 0.01 mM
PD91
active at 0.01 mM
penta-O-galloyl-beta-D-glucose
Piper betle ethanolic whole plant extract
-
42.3% inhibition at 2 mg/ml
-
Piper cueba ethanolic fruit extract
-
28.0% inhibition at 2 mg/ml
-
Piper kadsura ethanolic leaf extract
-
19.0% inhibition at 2 mg/ml
-
Piper kadsura ethanolic rhizome extract
-
36.5% inhibition at 2 mg/ml
-
Piper kadsura ethanolic root extract
-
39.2% inhibition at 2 mg/ml
-
Piper kadsura ethanolic stem extract
-
16.9% inhibition at 2 mg/ml
-
Piper longum ethanolic whole plant extract
-
12.3% inhibition at 2 mg/ml
-
Piper methysticum ethanolic leaf extract
-
28.4% inhibition at 2 mg/ml
-
Piper methysticum ethanolic rhizome extract
-
42.5% inhibition at 2 mg/ml
-
Piper methysticum ethanolic stem extract
-
21.9% inhibition at 2 mg/ml
-
Piper nigrum ethanolic fruit extract
-
63% inhibition at 2 mg/ml
-
Piper nigrum ethanolic leaf extract
-
53.0% inhibition at 2 mg/ml
-
Piper nigrum ethanolic stem extract
-
40.8% inhibition at 2 mg/ml
-
piperine
-
-
progesterone
riboflavin
-
-
sitosterol
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
SKF105657
-
a steroidal type II 5alpha-reductase specific inhibitor
soyasaponin I
-
0.1 mM, 66.8% inhibition
stearic acid
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
steroid carboxylic acid compounds
-
diverse, tricyclic aryl acid mimics of, overview
testosterone
theaflavin-3'-gallate
-
i.e. TF2b, from Thea sativa, inhibits the liver microsomal enzyme
theaflavin-3,3'-digallate
theaflavin-3-gallate
-
i.e. TF2a, from Thea sativa, inhibits the liver microsomal enzyme
tocopherol
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
turosteride
Unsaturated 3-carboxysteroids
-
VG106
active at 0.01 mM
yangonin
-
-
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
2-mercaptoethanol
-
3fold activity at 1 mM
3beta-acetoxy-16alpha-17alpha-epoxy-4-pregnen-20-one
-
-
3beta-acetoxy-5,16-pregnadien-20-one
-
-
4-pregnen-17-ol-3-one
-
-
androstandione
-
in male foreskin fibroblasts
androstenedione
-
in male foreskin fibroblasts
dihydrotestosterone
-
significantly increases 5alpha-R1 mRNA and 5alpha-R2 mRNA expression in male rats
dilauroylphosphatidylcholine
-
marked stimulatory effect on activity
dithiothreitol
iodoacetamide
-
stimulatory on solubilized enzyme from microsomes
morphine
-
morphine significantly reduces the testosterone concentration after acute and chronic exposure in the spinal cord. In contrast, the 5alpha-reductase 1 expression and of course dihydrotestosterone levels increase tfollowing chronic morphine administration
N-ethylmaleimide
-
stimulatory on solubilized enzyme from microsomes
Oxytocin
-
increases activity in human prostate epithelial cells
phosphatidylserine
-
4fold increase in activity
Phospholipids
-
stimulate
sulpiride
-
40 mg/kg doses induce mRNA expression of 5alphaR1 and 5alpha-R2; 40 mg/kg doses induce mRNA expression of 5alphaR1 and 5alpha-R2
testosterone
-
in female genital skin fibroblasts
additional information
-
oxytocin does not stimulate enzyme activity or expression in human prostate epithelial cells
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00057 - 0.00078
17-epitestosterone
0.00086
20alpha-hydroxypregn-4-en-3-one
-
-
0.0002 - 0.0005
20alpha-hydroxyprogesterone
0.0004 - 0.02634
androstenedione
0.000569 - 0.018
corticosterone
0.14
cortisone
-
-
0.00102 - 0.65
NADPH
0.000095 - 0.12
progesterone
0.0000013 - 0.0446
testosterone
additional information
additional information
-
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000006
(+)-LY191704
-
-
0.000004
(-)-LY191704
-
-
0.00092
(10bR)-8-chloro-4,10b-dimethyl-4a,5,6,10b-tetrahydrophenanthridin-2(1H)-one
-
isoform I
0.0011
(10bR)-8-chloro-4,5,10b-trimethyl-4a,5,6,10b-tetrahydrophenanthridin-2(1H)-one
-
isoform I
0.00026 - 0.0012
(4aS)-7-chloro-4a-methyl-2,3,4,4a-tetrahydrophenanthrene-2-carboxylic acid
0.000035
(5alpha,20-R)-4-Diazo-21-hydroxy-20-methylpregnan-3-one
-
at 25C formation of the reversible EI complex is not rate-limiting for enzyme inactivation, and this is expressed as saturation kinetics for the inhibition reaction
0.000085
17-diisopropylcarbamoyl-2-androsten-3-carboxylate
-
-
0.000007 - 0.000018
17-diisopropylcarbamoyl-3,5-androstadien-3-carboxylate
-
-
0.00003
17-diisopropylcarbamoyl-3-androsten-3-carboxyate
-
-
0.0022
17-diisopropylcarbamoyl-androstan-3-carboxylate
-
-
0.0045
17-tert-butylcarbamoyl-3,5-androstadien-3-carbaldehyde
-
-
0.000033
17-tert-butylcarbamoyl-3,5-androstadien-3-carboxylate
-
-
0.0042
17-tert-butylcarbamoyl-3,5-androstadien-3-ol
-
-
0.000036 - 0.0093
17beta-(N-tert-butylcarbamoyl)androsta-3,5-diene-3-carboxylic acid
0.026 - 0.036
17beta-estradiol
0.146
17beta-hydroxyandrosta-1,4-diene-3-one
-
-
0.000315 - 0.01
2,4a,9,10-tetrahydrophenanthrene-2-carboxylic acid
0.00006
20alpha-hydroxypregn-4-en-3-one
-
-
0.0049
4,16-androstadien-3-one
-
-
0.0000058
4,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I
0.0000062 - 0.0000118
4-Aza-4-methyl-5alpha-pregnane-3,20-dione
0.0126
4-bromo-17alpha-(p-fluorobenzoyloxy)-4-pregnene-3,20-dione
-
pH 6.0, 25C
0.000002 - 0.0000084
4-methyl-azasteroid
0.000026 - 0.01
7-bromo-2,4a,9,10-tetrahydrophenanthrene-2-carboxylic acid
0.00032 - 0.0025
7-chloro-2,4a,9,10-tetrahydrophenanthrene-2-carboxylic acid
0.0000027
8-chloro-4-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I
0.0000003 - 0.0041
acylate episteride
-
0.0000043 - 0.000017
dutasteride
0.000001 - 0.005
finasteride
0.000004
LY306089
-
-
0.0031
MK434
-
-
0.0043 - 0.0319
NADP+
0.00048 - 0.0027
penta-O-galloyl-beta-D-glucose
0.00086
progesterone
-
-
0.0026 - 0.0065
theaflavin-3'-gallate
0.00036 - 0.0056
theaflavin-3,3'-digallate
additional information
additional information
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00003
(+/-)-LY191704
Homo sapiens
-
i.e. (4aS,10aR)-7-chloro-1-methyl-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-one, non-steroidal, most potent benzoquinoline mimicing 4-azasteroid inhibitors, and specific for isozyme 5alphaR-1, IC50 is 30 nM
0.00076
(2E,4E,6E,8E)-((2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoate
Rattus norvegicus
-
pH not specified in the publication, temperature not specified in the publication
0.00053
(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl palmitoate
Rattus norvegicus
-
pH not specified in the publication, temperature not specified in the publication
0.44
(3R,4R)-3-(1,3-benzodioxol-5-ylmethyl)-4-(1,3,5-benzotrioxepin-6-ylmethyl)tetrahydrofuran-2-ol
1.03
(3R,4R)-3-(1,3-benzodioxol-5-ylmethyl)-4-(2,3-dimethoxybenzyl)tetrahydrofuran-2-ol
0.00072
(5'S)-17beta-(2-chlorophenyl-4,5-dihydrooxazol-5-yl)androst-5-en-3-one
Rattus norvegicus
-
pH 7.3, 37C
0.00105
(5'S)-17beta-(4-bromophenyl-4,5-dihydrooxazol-5-yl)androst-5-en-3-one
Rattus norvegicus
-
pH 7.3, 37C
0.00048
(Z)-((2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl) hexadec-9-enoate
Rattus norvegicus
-
pH not specified in the publication, temperature not specified in the publication
0.000026
17a-(2-propionoxyethyl)-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
Homo sapiens
P18405, P31213
pH not specified in the publication, 37C
0.000073
17a-allyl-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
Homo sapiens
P18405, P31213
pH not specified in the publication, 37C
0.000022
17a-ethyl-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
Homo sapiens
P18405, P31213
pH not specified in the publication, 37C
0.000054
17a-methyl-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
Homo sapiens
P18405, P31213
pH not specified in the publication, 37C
0.00005
17alpha-p-bromophenylcarbamoyloxy-4-pregnen-3 20-dione
0.00001
17alpha-phenylcarbamoyloxy-4-pregnen-3,20-dione
Homo sapiens
-
in the presence of 1 mM dithiothreitol, in 40 mM sodium phosphate buffer, at pH 6.5; with 1 mM dithiothreitol in 40 mM sodium phosphate buffer, at pH 6.5 and 37C
0.0000011
3beta-(3'-oxapentanoyloxy)-androst-5-en-17-one
Homo sapiens
-
pH 6.5, 37C
0.0000052
3beta-acetoxyandrost-5-en-17-one
Homo sapiens
-
pH 6.5, 37C
0.000000002
3beta-hexanoyloxyandrost-5-en-17-one
Homo sapiens
-
pH 6.5, 37C
0.00084
4-(3-(4-(N-methylacetamido)phenyl)pentan-3-yl)phenyl dibenzylcarbamate
Homo sapiens
-
-
0.14
Biochanin A
Rattus norvegicus
-
pH not specified in the publication, temperature not specified in the publication
0.000025
dehydroepiandrosterone
Homo sapiens
-
pH 6.5, 37C
0.37
equol
Rattus norvegicus
-
pH not specified in the publication, temperature not specified in the publication
0.81
ethinylestradiol
Rattus norvegicus
-
-
0.000008 - 0.008
finasteride
0.71
genistein
Rattus norvegicus
-
pH not specified in the publication, temperature not specified in the publication
0.086
ginsenoside Rg3
Rattus norvegicus
-
pH 7.2, 37C
0.259
ginsenoside Ro
Rattus norvegicus
-
pH 7.2, 37C
0.0005
MK386
Homo sapiens
-
-
0.48
piperine
Rattus norvegicus
-
-
0.017
riboflavin
Rattus norvegicus
-
pH not specified in the publication, temperature not specified in the publication
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.000000012
-
activity in dark grown cultures is slightly higher than in light grown cultures
0.00014
-
extract from shoot culture
0.00148
-
female
0.00234
-
male
0.03413
-
female
0.34
-
with NADPH
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5.2 - 5.6
-
mutant G34R
5.5 - 7.5
-
-
5.5
-
isozyme 2, low substrate concentration, efficiency optimum Vmax/Km
5.7
-
in testis microsomes of 5 month-old animals
5.8 - 7.5
-
-
6 - 6.5
-
mutant P181L
6.2
-
female
6.3
-
in testis microsomes of 6 month-old animals
7 - 9
-
human: 2 forms, 1. pH-optimum 5.5 (only in fibroblasts derived from genital skin), 2. pH-optimum 7-9 (in both genital and nongenital skin regions and in fibroblast from all skin regions)
7.3 - 7.6
-
-
8
-
recombinant monkey 5alpha-reductase isozyme 1
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
4.5 - 9
-
recombinant human 5alpha-reductase isozyme 1
4.5 - 9.5
-
recombinant human 5alpha-reductase isozyme 2
4.5 - 7.5
-
recombinant monkey 5alpha-reductase isozyme 2
4.5 - 9
-
pH .5: about 30% of activity maximum, pH 9.0: about 20% of activity maximum
5 - 8
-
pH 5.0: about 20% of activity maximum, pH 8.0: about 20% of activity maximum
5 - 8.5
-
at pH 5 and 8.5: about 50% of activity maximum
5.5 - 9
-
recombinant monkey 5alpha-reductase isozyme 1
6.3 - 7.5
-
-
6.5 - 8.6
-
half maximal activity at pH 6.5 and 8.6
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
15 - 42
-
15C: about 50% of activity maximum, 42C: about 30% of activity maximum
21 - 37
-
21C: about 50% of activity maximum, 37C: about 70% of activity maximum
additional information
-
-
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
adrenal 5alpha-reductase expression is decreased in male withdrawal seizure-prone mice
Manually annotated by BRENDA team
-
from beard and axillary hair and frontal scalp hair
Manually annotated by BRENDA team
-
the enzyme is detected in biopsies of pelvic endometriosis
Manually annotated by BRENDA team
-
both type 1 and type 2 isoenzyme, copy number of mRNA and activity of type 1 isoenzyme is significantly higher than type 2
Manually annotated by BRENDA team
-
external
Manually annotated by BRENDA team
-
similar 5alpha-R1 mRNA expression in female and male rats, 5alpha-R2 mRNA expression significantly higher in females than in males
Manually annotated by BRENDA team
-
type 2 isoenzyme
Manually annotated by BRENDA team
additional information
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
additional information
-
nuclear and cell-debris fraction
-
Manually annotated by BRENDA team